Last updated: 2026-10-13 11:58:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Bio-Rad Laboratories, Inc. (BIO) operates in the LABORATORY ANALYTICAL INSTRUMENTS sector and is listed on NYSE. The stock is currently priced at $364,53, with a market capitalization of $9,79B and a P/E ratio of 43,81. Over the past 52 weeks, its price has ranged from $236,73 to $396,23. This page covers its latest market performance, valuation, price trends and company information.
$9,79B | |
$369,85 | |
$832,70 | |
$46,54 | |
$366,16 | |
132,48K | |
275,53K | |
43,81 | |
$396,23 | |
$236,73 | |
-- | |
-- |
Bio-Rad Laboratories, Inc. (BIO) is trading at $368,35 in pre-market trading as of 2026-10-12 23:31:00, up 0,60% ($2,19) from the previous close of $366,16
Pre-market trading shows how investors are pricing BIO before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Bio-Rad Laboratories, Inc. (BIO) moved from $369,14 to $364,53, representing a decline of 1,25% ($4,61).
The stock traded between $353,97 and $390,00 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 221,39 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 80,1%
BIO is currently trading at $364,53, placing it 80,1% of the way from its 52-week low of $236,73 to its 52-week high of $396,23. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
| Industry | LABORATORY ANALYTICAL INSTRUMENTS |
| Employees | 7450 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Bio-Rad Laboratories, Inc. (BIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.